Dong-a St Co., Ltd.

Km Transderm Ltd.

Dong-a Pharm. Co., Ltd.

Sun-Woo Jang

Masaoki Goto

Hyun-Jung Kim

Kwang-Ho Cha

Chang-Yell Shin

Soon-Hoe Kim

Dong-Sung Kim

Yong-duck Kim

Jeong-Hoon Kim

Mi-Won Son

Moo-Hi Yoo

Ju-Mi Kim

Byoung-Ok Ahn

Kyung-Koo Kang

Seul-Min Choi

Mi-Jeong Seo

Jeong-Soo Kim

Hae-Sun Kim

Yong-Sung Shon

Kyung-Wan Ma

Myung-Joo Kang

Dong-Han Won

Sang-Min Hyun

Yong-Duck Kim

A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.

Percutaneous absorption preparation comprising stabilized donepezil

A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer ('SIS') as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.

Percutaneous absorption preparation for treating dementia comprising donepezil

The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treatment of degenerative arthritis). Specifically, the invention provides a highly physicochemically stable liquid injection, comprising piroxicam and hyaluronic acid as active ingredients and &#x3b2;-cyclodextrin or its derivative and polyethylene glycol as additives to enhance its physicochemical stability, and the preparation method thereof.

Stable liquid pharmaceutical composition containing piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt and the manufacturing method thereof

The present invention provides a 3',4&#x2032;,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. The 3&#x2032;,4&#x2032;,5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.

3',4&#x2032;,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same

Growing community of inventors

Seoul, South Korea

Sun-Woo Jang